1. Latest News
  2. Submit Press Release
Immune Response BioPharma, Inc. Logo

Immune Response BioPharma, Inc. Announces Formulation Changes to Blockbuster RA Drug RAVAX

Immune Response BioPharma, Inc. Announces Formulation Changes to Blockbuster RA Drug RAVAX Adds 4th Peptide for Potent RA Vaccine

 
PRLog - June 25, 2012 - NEW YORK -- Immune Response BioPharma, Inc. Today, June 25th 2012, Announces Formulation Changes to Blockbuster RA Drug RAVAX Adds 4th Peptide for Potent RA Vaccine.

       IRBP recognizes the need for safer and more tolerable yet effective Rheumatoid Arthritis treatments and adds a fourth TCR Poly-Peptide VB 12.1 to the RAVAX vaccine formulation, as it encompasses over 66% of patient gene types with RA. One of out five patient samples sequenced represented VB 12.1 thus we will add this important polypeptide; Human VB 12.1 DGYSVSRSKTEDFLL 66.7% will help us tweak the vaccine to show greater efficacy in the clinic. The new RAVAX encompasses Poly-Peptides BV 3, BV 14, BV 17 & BV 12.1.

             IRBP believes RAVAX is a first in class and best in class Rheumatoid Arthritis drug that can become treatment of choice for RA patients with under 10 years of diagnosed RA disease. "We are excited about the potential for RAVAX and our newly announced Phase 3 head to head clinical trial RAVAX vs. Humira or Rituxan coupled with Estrogen as 70% of patients are women. IRBP expects improved results showing RAVAX can become a blockbuster treatment for RA. We are actively seeking a funding partner to drive this unique and wonderful treatment to the finish line and FDA approval" IRBP CEO Mr. David Buswell

Immune Response BioPharma, Inc. maybe found on the Worldwide Web @ www.immuneresponsebiopharma.com

Immune Response BioPharma, Inc. develops lifesaving drugs and therapeutic vaccines in the auto-immune, infectious disease areas. The company's proprietary pipeline includes first in class treatments Remune for AIDS, NeuroVax for MS, RAVAX for RA and Sepsicillin for Sepsis Shock. Immune Response BioPharma, Inc. was incorporated in 2011 and is based in New York, New York.

--- End ---

Click to Share

Contact Email:
***@immuneresponsebiopharma.com Email Verified
Source:Immune Response BioPharma, Inc.
Phone:(917) 275-7931
Zip:10001
Location:New York City - New York - United States
Industry:Biotech, Health
Tags:Immune Response BioPharma Inc., RA Rheurmatoid Arthritis, drug, vaccine, clinical trials
Last Updated:Jun 25, 2012
Shortcut:prlog.org/11907877
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



Like PRLog?
9K2K1K
Click to Share